August 24 2016 Transenterix Director Andrea Biffi purchased 40 000 shares of the company at the average price of $1.4 on Monday August 22. Shares of Transenterix went up 13% after the news and closed at $1.62 on Tuesday.
August 19th, 2016. Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 – 31, 2016 in Rome, Italy. Presentation will be held at 10.19 CEST on August 30th.
Phase 2 has shown that treatment with A797 was well tolerated and resulted in meaningful, sustained increases in functional capacity and cardiac function in patients with LMNA-related DCM as measured by changes in 6MWT, NT-proBNP, LVEF and QoL.
August 3th, 2016. TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the first global sale of its ALF-XⓇ Surgical Robotic System to Humanitas Hospital in Milan, Italy.